TrialThe Journal of clinical investigation2026

Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer.

Yi Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.